Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Imperial College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Imperial College London, Medical Devices Deals, 2011 to YTD 2017 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Imperial College London, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Natera Enters into Agreement with Imperial College London and University of Leicester 12
Smith & Nephew Enters into Agreement with Imperial College London 13
Optibrium Enters into Partnership with Imperial College London and DNDi 14
Domainex Expands its Agreement with Imperial College London 15
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 16
Prosonix Enters Into Research Agreement With Imperial College London 17
UCB Enters Into Co-Development Agreement With Imperial College London 18
Medical Research Council, Imperial College, King’s College and UCL Form Joint Venture 19
ValiRx Enters Into Co-Development Agreement With Imperial College London 20
Imperial College London, King’s College London, University College London, Medical Research Council And GSK Form Joint Venture 21
Imperial College London – Key Competitors 23
Imperial College London – Key Employees 24
Imperial College London – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Joint Venture 25
Recent Developments 26
Strategy And Business Planning 26
Apr 06, 2016: UK’s First Commercial Synthetic Biology Foundry Goes Into Production 26
Government and Public Interest 27
Nov 15, 2017: Signalling protein found to drive heart scarring and organ failure 27
Oct 31, 2017: Revisiting abandoned treatments in fight against antimicrobial-resistant gonorrhea 28
Sep 25, 2017: Human antibodies from dengue patients can effectively treat Zika infection in mice 29
Sep 25, 2017: Antibody protects against both Zika and dengue, mouse study shows 31
Sep 06, 2017: Scientists link 153 new genetic variants to osteoporosis in largest ever study 33
May 12, 2017: A lead candidate for immunotherapy may increase tumour growth in certain cancers 34
Mar 17, 2017: Molecular therapy set to protect at-risk patients against heart attack and stroke 36
Oct 10, 2016: New study to tackle ADHD in young prisoners 37
Sep 22, 2016: Trust receives £90 million award for biomedical research 39
Sep 19, 2016: Parkinson’s disease protein plays vital ‘marshalling’ role in healthy brains 40
Sep 09, 2016: Activity of Huntington’s disease gene curbed for six months in mice 41
Jul 25, 2016: Flu vaccine may reduce risk of death for type 2 diabetes patients 43
May 17, 2016: Psilocybin for treatment-resistant depression 44
Mar 16, 2016: Antibiotic resistance ‘high among children with urinary tract infections’ 46
Mar 15, 2016: High antibiotic resistance levels in children could leave some treatments ineffective 47
Jan 06, 2016: Flu virus hijacking tactics revealed by scientists, paving way for new treatments 48
Product News 49
Oct 13, 2016: Shanghai Medicilon: Researchers Create A Gene Therapy Treatment That May Prevent Alzheimer Disease 49
Sep 27, 2016: Blood pressure drug may boost effectiveness of lung cancer treatment 51
Jul 28, 2016: Two New Scientific Studies Confirm Benefits of Orafti Synergy1 in Reducing the Risk of Diabetes 52
Other Significant Developments 53
Nov 08, 2017: NPL and Imperial College London Launch a New Virtual Lab to Establish the UK Centre for Engineering Biology, Metrology and Standards 53
Nov 29, 2016: Global research network hunts the missing link between genetics and environmental factors to unlock the secrets of global diseases such as cancer and diabetes to revolutionise healthcare 54
Feb 02, 2016: Heptares Launches “Orbit” Initiative – A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS) 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
Imperial College London, Pharmaceuticals & Healthcare, Key Facts 2
Imperial College London, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Imperial College London, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Imperial College London, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Imperial College London, Deals By Therapy Area, 2011 to YTD 2017 9
Imperial College London, Medical Devices Deals, 2011 to YTD 2017 10
Imperial College London, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Natera Enters into Agreement with Imperial College London and University of Leicester 12
Smith & Nephew Enters into Agreement with Imperial College London 13
Optibrium Enters into Partnership with Imperial College London and DNDi 14
Domainex Expands its Agreement with Imperial College London 15
Protectimmun Enters into Research Agreement with Janssen Biotech And Imperial College 16
Prosonix Enters Into Research Agreement With Imperial College London 17
UCB Enters Into Co-Development Agreement With Imperial College London 18
Medical Research Council, Imperial College, King's College and UCL Form Joint Venture 19
ValiRx Enters Into Co-Development Agreement With Imperial College London 20
Imperial College London, King's College London, University College London, Medical Research Council And GSK Form Joint Venture 21
Imperial College London, Key Competitors 23
Imperial College London, Key Employees 24
Imperial College London, Subsidiaries 25
Imperial College London, Joint Venture 25